湖北宜化(000422.SZ):聯合化工合成氨及尿素裝置臨時停產
格隆匯12月20日丨湖北宜化(000422.SZ)公佈,公司於2021年12月20日接到本公司子公司內蒙古鄂爾多斯聯合化工有限公司(以下簡稱“聯合化工”)的通知,因冬季天然氣供應受限,聯合化工合成氨及尿素裝置於2021年12月20日起全部停產。
聯合化工本次臨時停產預計減少公司2021年度營業收入8140.91萬元,減少歸屬於母公司所有者的淨利潤約867萬元左右;該預計是公司財務部門初步測算的結果,具體數據應以公司2021年年度審計數據為準。公司將積極協調聯合化工的天然氣供應,爭取使聯合化工早日恢復生產。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.